Brand Identity, Logo Design, Communication Materials and a new Web Platform made in ComeUP for the Startup ADDAX Biosciences in partnership with the University of Turin and 2i3T Incubator.
ADDAX Biosciences proposes a revolution in the fixative market by the introduction of GAF, an innovative reagent that will allow the optimal tissue fixation at structural and molecular level combined with the absence of toxicity and carcinogenic activity.
ADDAX Biosciences introduces into the market a histological fixative as alternative to Formalin, a toxic and canginogenic agent, based on an innovative glyoxal solution: Acid Deprived DiAldehyde FiXative (GAF). The results have been published in an international peer reviewed journal (Plos One 12:e0182965; 2017).
The scientific problem addressed with our project – ADDAX Biosciences – has been completely developed in the context of the University of Torino. Prof. Gianni Bussolati, full Professor of Pathology for over 40 years, focused his research for several years on the optimal fixation of tissues, with the goal of achieving optimal structural and molecular tissue preservation to allow the correct diagnostic and therapy of tumor pathologies. The idea and validation of the nontoxic fixative, proposed by ADDAX Biosciences, has been performed in collaboration with a team at the Department of Medical Sciences at the University of Torino and at the IRCCS Candiolo Cancer Institute.
The chemical and biotechnological development of the idea has been further expanded by Prof. Benedetta Bussolati at the Department of Molecular Biotechnology and Health Sciences of the University of Torino. The ADDAX Biosciences has been proposed to the Department and accepted as academic spin-off last 2nd October 2017. Our project ADDAX Biosciences is comprised in the Third Mission project of our University.